Asia-Pacific Bladder Cancer Therapeutics Market estimated to grow with a CAGR of 5.68% in the coming five years (2016–2021)

RESEARCH REPORT
JUN 2017
Bladder Cancer Therapeutics Market (2016-2021)
SEGMENTED BY SENSOR TYPE, BY TECHNIQUE, BY APPLICATION, BY LIGHT
EQUIPMENT, BY REGION AND END USERS, INDUSTRY ANALYSIS, SIZE, SHARE,
GROWTH TRENDS AND FORECASTS REPORTS
2016-2021

The Asia-Pacific “Bladder Cancer Therapeutics Market” research report, published by
Market Data Forecast estimates that the market itself was worth $80.8 million in 2016 and
expected to grow at a CAGR of 5.68%, to reach $106.6 million by 2021.
The bladder is a hollow organ in the lower part of the abdomen that stores urine until it is
passed out of the body.
The most common type of bladder cancer is transitional cell carcinoma, which begins in
urothelial cells that line the inside of the bladder. Urothelial cells are transitional cells, which
are able to change shape and stretch when the bladder is full. This type of cancer is also
called urothelial carcinoma. Other types of bladder cancer include squamous cell carcinoma
(cancer that begins in thin, flat cells lining the bladder) and adenocarcinoma (cancer that
begins in cells that make and release mucus and other fluids).
Request Free Sample: http://www.marketdataforecast.com/market-reports/asia-pacificbladder-cancer-therapeutics-market-1152/request-sample
People who smoke have an increased risk of bladder cancer. Being exposed to certain
chemicals and having chronic bladder infections can also increase the risk of bladder cancer.
The most common sign of bladder cancer is blood in the urine. Bladder cancer is often
diagnosed at an early stage, when the cancer is easier to treat.
The report also presents detailed analysis of multitude of factors affecting the Bladder
Cancer Therapeutics market bearing either positive or negative outcomes. Some of those
factors are:
Rising healthcare expenditure
Increasing cancer patient population
Growing involvement of universities & research institutes
Rising focus of foreign pharmaceutical companies on Asian market
Unawareness among bladder cancer patients about advanced cancer therapies
Presence of more number of generic bladder cancer therapeutics
For granular level understanding the Bladder Cancer Therapeutics Market is segmented
based on product and application, each being provided with Market Size Estimates and Y-o-
Y Forecasts. Asia-Pacific Bladder Cancer Therapeutics market is segmented based on type
and treatment. Based on type, the market is further sub-segmented as Transitional Cell
Bladder Cancer, Non Muscle Invasive/Superficial Bladder Cancer, Invasive Bladder Cancer,
Squamous Cell Bladder Cancer, Adenocarcinoma of the Bladder, and Rare Bladder Cancers.
Based on treatment, the market is further segmented as Surgery, Chemotherapy,
Immunotherapy, Radiation Therapy, and Intravesical Therapy.
The Asia-Pacific region is geographically segmented into China, India, Japan, South Korea,
and Australia. The Asia-Pacific region is projected to grow at the highest CAGR during the

forecast period due to reasons such as rising aging population and increasing participation
of several private & public establishments to organize awareness programs on Bladder
Cancer.
The key players in Bladder Cancer Therapeutics market include, Sanofi S.A. (France),
Novartis AG (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Eli Lilly and Company
(U.S.), AstraZeneca plc (U.K.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche Ltd.
(Switzerland), and Celgene Corporation (U.S.).
The Asia-Pacific Bladder Cancer Therapeutics Market report offers wide-range of scope:
Regional and country-level analysis that provides an individual perspective of Asia-
Pacific region and the aforementioned countries
Know more about key areas of industry growth via detailed Segment-level analysis
on basis of product type long with market size forecasts and y-o-y estimations
Detailed explanation of major drivers, restraints, opportunities, and
challenges(DROC) that affect the market and impact the ever-shifting market
dynamics

TABLE OF CONTENTS
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.3 Analysis Design
2.4 Study Timeline
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
Customize the report: http://www.marketdataforecast.com/market-reports/asia-pacificbladder-cancer-therapeutics-market-1152/customize-report
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis
(DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
Inquire Before Buying: http://www.marketdataforecast.com/market-reports/asia-pacificbladder-cancer-therapeutics-market-1152/inquire
5. Market Segmentation
5.1 By Type
5.1.1 Transitional Cell Bladder Cancer
5.1.2 Non Muscle Invasive/Superficial Bladder Cancer

5.2 By Treatment
5.1.3 Invasive Bladder Cancer
5.1.4 Squamous Cell Bladder Cancer
5.1.5 Adenocarcinoma of the Bladder
5.1.6 Rare Bladder Cancers
5.2.1 Surgery
5.2.2 Chemotherapy
5.2.3 Immunotherapy
5.2.4 Radiation Therapy
5.2.5 Intravesical Therapy
Request Discount: http://www.marketdataforecast.com/market-reports/asia-pacificbladder-cancer-therapeutics-market-1152/request-discount
6. Geographical Analysis
6.1 Asia-Pacific
6.1.1 Introduction
6.1.2 China
6.1.3 India
6.1.4 Japan
6.1.5 South Korea
6.1.6 Australia
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal

8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 Sanofi S.A. (France)
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.2 Novartis AG (Switzerland)
9.3 Pfizer Inc. (U.S.)
9.4 GlaxoSmithKline plc (U.K.)
9.5 Eli Lilly and Company (U.S.)
9.6 AstraZeneca plc (U.K.)
9.7 Bristol-Myers Squibb (U.S.)
9.9 F. Hoffmann-La Roche Ltd. (Switzerland)
9.10 Celgene Corporation (U.S.)
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities

SCOPE OF THE REPORT
Regional and country-level analysis and forecasts of the study market; providing
Insights on the major countries/regions in which this industry is blooming and to also
identify the regions that are still untapped
Segment-level analysis in terms of technology, component, and type along with
market size forecasts and estimations to detect key areas of industry growth in detail
Identification of key drivers, restraints, opportunities, and challenges (DROC) in the
market and their impact on shifting market dynamics
Study of the effect of exogenous and endogenous factors that affect the global
market; which includes broadly demographic, economics, and political, among other
macro-environmental factors presented in an extensive PESTLE Analysis
Study the micro environment factors that determine the overall profitability of an
Industry, using Porter’s five forces analysis for analyzing the level of competition
and business strategy development
A comprehensive list of key market players along with their product portfolio,
current strategic interests, key financial information, legal issues, SWOT analysis and
analyst overview to study and sustain the market environment
Competitive landscape analysis listing out the mergers, acquisitions, collaborations
in the field along with new product launches, comparative financial studies and
recent developments in the market by the major companies
An executive summary, abridging the entire report in such a way that decisionmaking
personnel can rapidly become acquainted with background information,
concise analysis and main conclusions

ABOUT US
Market Data Forecast is a firm working in the areas of market research and business
intelligence. We have rich experience in research across various business domains and we
cater to the needs of both individual and corporate clients. Our research services assist
clients in key business areas like business process improvement, key decision making and
developing appropriate corporate strategy. We are truly committed to our clients and other
stakeholders for providing customized research services of the highest quality.
CONTACT INFORMATION
We always look forward to working with new clients, pushing our boundaries and extending
our reach beyond global horizons. Get in touch with us for further queries.
Abhishek Shukla
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail: abhishek@marketdataforecast.com
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
FOR MORE INFORMATION